Cargando…

Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England

BACKGROUND: Contradicting assumptions have been made about the effectiveness of SARS-CoV-2 vaccines in patients with multiple sclerosis (MS) receiving immunomodulatory disease-modifying therapies (DMTs) based on the quantification of humoral and cellular immune responses. This study aimed to underst...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garjani, Afagh, Patel, Sameer, Bharkhada, Dhiren, Rashid, Waqar, Coles, Alasdair, Law, Graham R, Evangelou, Nikos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645279/ https://www.ncbi.nlm.nih.gov/pubmed/34896876 http://dx.doi.org/10.1016/j.msard.2021.103458

Ejemplares similares

Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register
por: Garjani, Afagh, et al.
Publicado: (2021)

COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies
por: Garjani, Afagh, et al.
Publicado: (2021)

An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis
por: Dumitrescu, Laura, et al.
Publicado: (2023)

To the editors: Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England
por: Tugemann, Bastian, et al.
Publicado: (2022)

Impact of the COVID-19 pandemic on the prescription of disease-modifying therapy for multiple sclerosis in England: a nationwide study
por: Williams, Thomas, et al.
Publicado: (2022)

Decentralised clinical trials in multiple sclerosis research
por: Garjani, Afagh, et al.
Publicado: (2022)

Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register
por: Evangelou, Nikos, et al.
Publicado: (2021)

Challenges of developing, conducting, analysing and reporting a COVID-19 study as the COVID-19 pandemic unfolds: an online co-autoethnographic study
por: das Nair, Roshan, et al.
Publicado: (2021)

Newer therapies for multiple sclerosis
por: Coles, Alasdair
Publicado: (2015)

Association Between Platelet Count as a Noninvasive Marker and Ultrasonographic Grading in Patients With Nonalcoholic Fatty Liver Disease
por: Garjani, Afagh, et al.
Publicado: (2015)

Promoting remyelination in multiple sclerosis
por: Cunniffe, Nick, et al.
Publicado: (2019)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Immunomodulatory Effects of Exercise in Experimental Multiple Sclerosis
por: Gentile, Antonietta, et al.
Publicado: (2019)

Role of oral teriflunomide in the management of multiple sclerosis
por: Tanasescu, Radu, et al.
Publicado: (2013)

Interferon (IFN)-λ Takes the Helm: Immunomodulatory Roles of Type III IFNs
por: Zanoni, Ivan, et al.
Publicado: (2017)

Development of oral immunomodulatory agents in the management of multiple sclerosis
por: Nicholas, Richard, et al.
Publicado: (2011)

348 Immunomodulatory Effects of Extracorporeal Photochemotherapy in Systemic Sclerosis
por: Zeher, Margit, et al.
Publicado: (2012)

It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug
por: Mesa-Arango, Ana C., et al.
Publicado: (2012)

Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review
por: Furgiuele, Alessia, et al.
Publicado: (2021)

Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom
por: Abdel-mannan, Omar A., et al.
Publicado: (2021)

School Lunch Take up and Attainment in Primary and Secondary Schools in England
por: Nelson, Michael, et al.
Publicado: (2015)

Usability and acceptability of a cognitive training intervention (SMART) for people with multiple sclerosis (MS): A prefeasibility formative evaluation
por: Frost, Alexandra C., et al.
Publicado: (2022)

Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort study
por: Papathanasiou, Athanasios, et al.
Publicado: (2023)

Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity
por: Ostkamp, Patrick, et al.
Publicado: (2021)

Immunomodulatory Potential of Human Mesenchymal Stem Cells and their Exosomes on Multiple Sclerosis
por: Baharlooi, Hussein, et al.
Publicado: (2022)

Enhancing antimicrobial surveillance in hospitals in England: a RAND-modified Delphi
por: Patel, Selina, et al.
Publicado: (2022)

Disease Modifying Agents for Multiple Sclerosis
por: Hilas, Olga, et al.
Publicado: (2010)

Immunomodulatory function of the cystic fibrosis modifier gene BPIFA1
por: Saferali, Aabida, et al.
Publicado: (2020)

Strengthening Mental Abilities with Relational Training (SMART) in multiple sclerosis (MS): study protocol for a feasibility randomised controlled trial
por: Golijani-Moghaddam, Nima, et al.
Publicado: (2022)

Monitoring access to nationally commissioned services in England
por: Coles, Suzanne, et al.
Publicado: (2012)

Microglia Activation and Immunomodulatory Therapies for Retinal Degenerations
por: Rashid, Khalid, et al.
Publicado: (2018)

Immunomodulatory and anti-inflammatory effects of probiotics in multiple sclerosis: a systematic review
por: Morshedi, Mohammad, et al.
Publicado: (2019)

Current Take on Systemic Sclerosis Patients’ Vaccination Recommendations
por: Murdaca, Giuseppe, et al.
Publicado: (2021)

The costs of treating vaginal and vulval cancer in England (2009–2015)
por: Stephens, Stephanie, et al.
Publicado: (2020)

Acute kidney injury: taking aim at colistin
por: Rashid, Shayan, et al.
Publicado: (2014)

Lactobacillus mucosae DPC 6426 as a bile-modifying and immunomodulatory microbe
por: Ryan, Paul M., et al.
Publicado: (2019)

The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation
por: Hooftman, Alexander, et al.
Publicado: (2020)

Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients
por: Georgieva, Zoya G, et al.
Publicado: (2021)

Brain Tumours: Rise in Glioblastoma Multiforme Incidence in England 1995–2015 Suggests an Adverse Environmental or Lifestyle Factor
por: Philips, Alasdair, et al.
Publicado: (2018)

Increased THEMIS First Exon Usage in CD4+ T-Cells Is Associated with a Genotype that Is Protective against Multiple Sclerosis
por: Davies, Jessica L., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7lmffhmis2betsa240uv2eag40